GLP – 3 – Retatrutide is a next-generation synthetic peptide that acts as a triple agonist of GLP-1, GIP, and glucagon receptors. This multi-receptor targeting is being researched for its ability to promote significant weight loss, improve insulin sensitivity, enhance glucose tolerance, and support cardiovascular health. Clinical studies suggest it may substantially reduce body fat while addressing multiple metabolic risk factors.